Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography
ConclusionThe results of this study suggest that CEUS at 5 weeks after initiation of Atezo + Bev may predict PFS in HCC patients. Changes to the treatment plan may need to be considered in patients with post AUC > 61.3.
Source: Journal of Medical Ultrasonics - Category: Radiology Source Type: research
More News: Avastin | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Radiology | Study